

## BICO Group AB (publ) announces an increase in number of shares and votes

**The number of shares and votes in BICO Group AB (publ) have increased following the exercise of 80,000 warrants pursuant to the company's warrant programme 2018, whereby 80,000 shares of series B were subscribed. The Swedish Companies Registration Office has during the month of January registered the new shares of series B.**

As of January 31, 2023, the total number of registered and outstanding shares in BICO Group AB (publ) amounts to 70,574,895, whereof 1,500,000 are shares of series A, together carrying in total 15,000,000 votes, and 69,074,895 are shares of series B, together carrying in total 69,074,895 votes. The total number of votes amounts to 84,074,895. The share capital amounts to SEK 1,764,372.375. The company does not hold any treasury shares.

**For further information, please contact:**

Åsa Hillsten, Senior Advisor Investor Relations, BICO Group AB

Phone: +46 70-081 81 17

Email: [ash@bico.com](mailto:ash@bico.com)

*This information is information that BICO Group is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2023-01-31 15:30 CET.*

### **About BICO**

BICO is a leading provider of life science solutions and laboratory automation that enable more efficient development of new treatments with more specificity and less need for animal testing.

The company uses bioconvergence as its operating system, combining advanced technologies with biology to streamline and automate workflows within the pharmaceutical and biopharma industries.

With 32,000+ instruments installed in over 65 countries, BICO products and solutions are found in more than 3,500 laboratories, including the world's top 20 pharmaceutical companies, and have been cited in over 11,000 publications.

Operating through three business areas – Bioprinting, Biosciences and Bioautomation – the BICO Group strives towards the long-term ambition of enabling the reduction of the world's organ shortage and speeding up drug development to create the future of life-saving treatments.

BICO is listed on Mid-Cap, Nasdaq Stockholm under BICO. [www.bico.com](http://www.bico.com)

### **Attachments**

**[BICO Group AB \(publ\) announces an increase in number of shares and votes](#)**